Mesoblast Limited (MESO) 6-K Current report (foreign)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of July 2023

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On July 7, 2023, Mesoblast Limited filed with the Australian Securities Exchange a notification of issue, conversion or payment up of equity securities (Appendix 3G) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On July 7, 2023, Mesoblast Limited filed with the Australian Securities Exchange a notification of cessation of securities (Appendix 3H) which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

On July 7, 2023, Mesoblast Limited filed with the Australian Securities Exchange a change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.3 and Exhibit 99.4, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: July 12, 2023

INDEX TO EXHIBITS

Item
99.1	Appendix 3G of Mesoblast Ltd, dated July 7, 2023
99.2	Appendix 3H of Mesoblast Ltd, dated July 7, 2023
99.3	Appendix 3Y of Mesoblast Ltd, dated July 7, 2023
99.4	Appendix 3Y of Mesoblast Ltd, dated July 7, 2023